Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease

Labaere, Delphine; Smismans, Annick; Olmen, August Van; Christiaens, Paul; D’Haens, Geert R.; Moons, Veerle; Cuyle, Pieter-Jan; Frans, Johan; Bossuyt, Peter

doi:10.1177/2050640613518201

Cited by 126 publications

(93 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only a few methods correlated between each other, and substantial quantitative differences between the assays have been observed [38]. Due to this variation, it is impossible to use those methods interchangeably to follow-up IBD.…”

Section: Methods For Measurement Of Fecal Calprotectinmentioning

confidence: 99%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response.

show abstract

Section: Methods For Measurement Of Fecal Calprotectinmentioning

confidence: 99%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…In addition, results are rapidly available, which allows quick clinical decision making. However, as laboratories are being consolidated, more automated assays such as enzyme-linked immunoassays (ELISA) [7,22,23], chemiluminescence immunoassays (CLIA), fluoro enzyme immunoassays (FEIA) and particle enhanced turbidimetric immunoassays (PETIA) for the measurement of faecal calprotectin have been introduced [10].…”

Section: Introductionmentioning

confidence: 99%

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Oyaert

Boel

Jacobs

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Background: We evaluated the analytical performance of six different faecal calprotectin immunoassays together with their diagnostic accuracy in the discrimination between functional and organic bowel disorders. Methods: The faecal samples were obtained from inflammatory bowel disease patients (n = 27) at the time of diagnosis [Crohn's disease (n = 15), colitis ulcerosa (n = 12)], gastroenterologic disease control patients (n = 52) and rheumatologic disease control patients (n = 26). All individuals included in the study underwent a concurrent ileocolonoscopy. Analytical performance (imprecision, accuracy, carry-over, correlation and agreement) and diagnostic accuracy (sensitivity, specificity, likelihood ratios) of the different assays were evaluated. Results: All methods demonstrated good analytical performance, but within-run and total imprecision varied depending on the assay methodology used. Using Passing Bablok and Bland-Altman analyses, low quantitative agreement was observed between the assays. All assays showed excellent diagnostic accuracy, with areas under the receiver operating characteristic curves (ROC) ranging from 0.974 to 0.998. The AUCs were not significantly different between assays (p > 0.05). Diagnostic sensitivity at the

show abstract

“…The addition of this subscore to the mPDAI score resulted in a new score (Cal-mPDAI) showing specificity comparable to PDAI for the diagnosis of pouchitis and increased sensitivity when compared to mPDAI. The advantage of this approach is inherent to the fact that calprotectin measurement could be done during the same endoscopic session using the newly developed ELISA tests, which are easier and faster to be performed when compared to previous tests (21). Moreover, calprotectin measurement may reflect the global inflammatory activity of the pouch, possibly overcoming the disadvantage of histological examination related to the patchy expression of inflammation.…”

Section: Discussionmentioning

confidence: 99%

Endoluminal calprotectin measurement in assessment of pouchitis and a new index of disease activity: A pilot study

Pronio¹,

Filippo²,

Mariani³

et al. 2016

Rev Esp Enferm Dig

View full text Add to dashboard Cite

Pouchitis is the most common complication following proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis (UC). To provide a standardized definition of pouchitis clinical, endoscopic and histological markers were grouped and weighted in the pouch disease activity index (PDAI). However, the delay in the assessment of the final score due to the time requested for histological analysis remains the main obstacle to the index implementation in clinical practice so that the use of modified-PDAI (mPDAI) with exclusion of histologic subscore has been proposed. We tested the ability of calprotectin measurement in the pouch endoluminal content to mimic the histologic score as defined in the PDAI, the index that we adopted as gold standard for pouchitis diagnosis. Calprotectin was measured by ELISA in the pouch endoluminal content collected during endoscopy in 40 consecutive patients with J-pouch. In each patient PDAI and mPDAI were calculated and 15% of patients were erroneously classified by mPDAI. ROC analysis of calprotectin values vs. acute histological subscore ≥ 3 identified different calprotectin cut-off values with corresponding sensitivity and specificity allowing the definition and scoring of different range of calprotectin subscores. We incorporated the calprotectin score in the mPDAI obtaining a new score that shows the same specificity as PDAI for diagnosis of pouchitis and higher sensitivity when compared with mPDAI. The use of the proposed new score, once validated in a larger series of patients, might be useful in the early management of patients with symptoms of pouchitis.

show abstract

Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease

Cited by 126 publications

References 16 publications

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease

Endoluminal calprotectin measurement in assessment of pouchitis and a new index of disease activity: A pilot study

Contact Info

Product

Resources

About